The Clorox Company $CLX Shares Sold by 111 Capital

111 Capital lessened its position in The Clorox Company (NYSE:CLX) by 51.0% in the 2nd quarter, Holdings Channel reports. The fund owned 1,792 shares of the company’s stock after selling 1,863 shares during the period. 111 Capital’s holdings in Clorox were worth $215,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Park Avenue Securities LLC acquired a new position in Clorox in the 1st quarter valued at approximately $258,000. Wedge Capital Management L L P NC increased its stake in shares of Clorox by 33.5% during the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company’s stock worth $4,198,000 after purchasing an additional 7,159 shares during the last quarter. Courier Capital LLC grew its stake in Clorox by 11.6% in the 1st quarter. Courier Capital LLC now owns 2,785 shares of the company’s stock valued at $410,000 after buying an additional 290 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Clorox by 25.4% in the 1st quarter. Farther Finance Advisors LLC now owns 5,872 shares of the company’s stock valued at $869,000 after buying an additional 1,190 shares during the last quarter. Finally, Pallas Capital Advisors LLC acquired a new position in Clorox in the 1st quarter valued at $647,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Insider Activity at Clorox

In other news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. The trade was a 21.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is currently owned by corporate insiders.

Clorox Trading Up 1.5%

Shares of NYSE CLX opened at $120.49 on Wednesday. The Clorox Company has a 1-year low of $116.53 and a 1-year high of $171.37. The company has a market cap of $14.74 billion, a PE ratio of 18.48, a P/E/G ratio of 0.97 and a beta of 0.52. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The company has a 50-day moving average of $122.51 and a two-hundred day moving average of $129.17.

Clorox (NYSE:CLX) last announced its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same period in the previous year, the firm posted $1.82 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities analysts expect that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. The ex-dividend date is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a dividend yield of 4.1%. Clorox’s payout ratio is currently 76.07%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CLX. TD Cowen decreased their price target on shares of Clorox from $120.00 to $117.00 and set a “hold” rating on the stock in a research report on Wednesday, October 1st. Morgan Stanley reduced their price objective on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating for the company in a report on Friday, August 1st. Zacks Research raised shares of Clorox from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Jefferies Financial Group reduced their price objective on shares of Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Finally, UBS Group reduced their price objective on shares of Clorox from $150.00 to $134.00 and set a “neutral” rating for the company in a report on Thursday, July 17th. One investment analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $134.08.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.